The effects of metformin on vascular function and adipocyte AMP-activated protein kinase (AMPK) activation in type 2 diabetes

Completed

• Conditions: Type 2 diabetes; Nutritional, Metabolic, Endocrine; Non-insulin-dependent diabetes mellitus

• Registration Number: ISRCTN51336867
• Lead Sponsor: Greater Glasgow Health Board (North Glasgow University Hospitals Division) (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06-29
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

1. Body mass index (BMI) range 27 - 40 kg/m2
2. HbA1c greater than 7% but less than 11% (Diabetes Control and Complications Trial [DCCT]) at screening
3. Previously treated with diet alone or oral monotherapy (i.e., metformin or sulphonylurea). Subjects on monotherapy had discontinued medication during the six-week run-in period.
4. Males, aged between 50 - 70 years

Exclusion Criteria

1. Subjects on warfarin treatment
2. Subjects treated with insulin currently or in the previous 12 months
3. Previous intolerance of metformin or sulphonylurea
4. Presence of contra-indication to metformin therapy for example renal disease or congestive cardiac failure
5. Cardiovascular event (i.e., electrocardiogram (ECG)/troponin proven myocardial infarction [MI] or cerebrovascular accident [CVA]) in previous 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified